---
title: "Century Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295663105.md"
datetime: "2026-08-12T12:15:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295663105.md)
  - [en](https://longbridge.com/en/news/295663105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295663105.md)
generator: "portal-rs"
---

# Century Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.17.

EBIT: As of FY2026 Q2, the actual value is USD -36.53 M.

#### Cash Position

Century Therapeutics, Inc. reported cash, cash equivalents, and investments of $197.2 million as of June 30, 2026, an increase from $117.1 million as of December 31, 2025.

#### Research and Development (R&D) Expenses

R&D expenses for the quarter ended June 30, 2026, were $19.6 million, a decrease from $26.9 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $36.7 million, compared to $53.439 million for the six months ended June 30, 2025. This reduction was primarily due to a decrease in personnel and facility costs following portfolio prioritization.

#### General and Administrative (G&A) Expenses

G&A expenses were $5.8 million for the quarter ended June 30, 2026, down from $7.8 million for the same period in 2025. For the six months ended June 30, 2026, G&A expenses totaled $12.366 million, compared to $16.212 million for the six months ended June 30, 2025.

#### Net Income (Loss)

Net loss for the quarter ended June 30, 2026, was - $34.6 million, compared to a net loss of - $32.5 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $56.195 million, contrasting with a net income of $44.019 million for the six months ended June 30, 2025.

#### Other Financial Metrics

-   Loss on lease component termination was $11.145 million for both the three and six months ended June 30, 2026.
-   Total operating expenses were $36.527 million for the quarter ended June 30, 2026, and $60.211 million for the six months ended June 30, 2026.
-   Income (loss) from operations was - $36.527 million for the quarter ended June 30, 2026, and - $60.221 million for the six months ended June 30, 2026.
-   Interest income was $1.982 million for the quarter ended June 30, 2026, and $4.001 million for the six months ended June 30, 2026.
-   Total assets were $287.006 million as of June 30, 2026, up from $223.704 million as of December 31, 2025.
-   Total liabilities were $54.661 million as of June 30, 2026, down from $64.768 million as of December 31, 2025.
-   Total stockholders’ equity was $232.345 million as of June 30, 2026, up from $158.936 million as of December 31, 2025.

#### Operational Highlights

Century Therapeutics, Inc. completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy. Preclinical data for CNTY-813 demonstrated durable glucose control in vivo, immune evasion, and successful manufacturing at clinical scale. The company also established its Phase 1 clinical manufacturing bioreactor process for CNTY-813.

#### Outlook and Guidance

Century Therapeutics, Inc. expects to submit an Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027. CNTY-308 is projected to enter the clinic in 2026. The current cash, cash equivalents, and investments are estimated to support operations into the first quarter of 2029.

### Related Stocks

- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)

## Related News & Research

- [Century Therapeutics Reports Q2 Results, Pipeline Advancements](https://longbridge.com/en/news/295668584.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**